Home > Insider Trading > Filing (0000899243-20-014715)

Filing Details

Accession Number:: 0000899243-20-014715
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-06-01 16:05:54
Reporting Period:: 2020-05-28

Accepted Time:: 2020-06-01 16:05:54
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1596946	Quotient Ltd	QTNT	In Vitro & In Vivo Diagnostic Substances (2835)	264719797

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1604629	Edward Farrell	C/O Quotient Limited 28 Esplanade St Helier Y9 JE2 3QA	Chief Operating Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Disposition	2020-05-28	12,811	$7.40	29,013	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Ordinary Shares	Employee Stock Option (right to buy)	$11.92	2026-05-31	30,000	30,000	Direct
Ordinary Shares	Employee Stock Option (right to buy)	$15.17	2025-05-19	30,000	30,000	Direct
Ordinary Shares	Options to acquire ordinary shares	$0.00	2023-04-10	96,000	96,000	Direct
Ordinary Shares	Employee Stock Option (right to buy)	$8.00	2024-04-29	79,000	79,000	Direct
Ordinary Shares	Employee Stock Option (right to buy)	$7.58	2027-05-23	40,000	40,000	Direct
Ordinary Shares	Restricted Stock Units	$0.00		12,257	12,257	Direct
Ordinary Shares	Restricted Stock Units	$0.00		30,000	30,000	Direct
Ordinary Shares	Restricted Stock Units	$0.00		2,232	2,232	Direct
Ordinary Shares	Restricted Stock Units	$0.00		55,000	55,000	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2026-05-31	30,000	30,000	Direct
2025-05-19	30,000	30,000	Direct
2023-04-10	96,000	96,000	Direct
2024-04-29	79,000	79,000	Direct
2027-05-23	40,000	40,000	Direct
	12,257	12,257	Direct
	30,000	30,000	Direct
	2,232	2,232	Direct
	55,000	55,000	Direct

Footnotes

Restricted Stock Units convert into ordinary shares on a one-for-one basis.
All 30,000 options have vested and remain exercisable.
All 30,000 options have vested and remain exercisable.
The exercise price will be paid in pounds sterling, at GBP0.003 per share.
All 96,000 options have vested and remain exercisable.
All 79,000 options have vested and remain exercisable.
All 40,000 options have vested and remain exercisable.
On May 24, 2018, the Reporting Person was granted 36,773 Restricted Stock Units, of which 24,516 have vested and have been exercised. The remaining 12,257 Restricted Stock Units will vest on May 24, 2021.
On May 24, 2019, the Reporting Person was granted 45,000 Restricted Stock Units, of which 15,000 have vested and have been exercised. The remaining 30,000 Restricted Stock Units will vest in two equal installments on May 24, 2021 and May 24, 2022.
On January 7, 2020, the Reporting Person was granted 2,232 Restricted Stock Units, vesting in three equal annual installments beginning January 7, 2021.
On May 24, 2020, the Reporting Person was granted 55,000 Restricted Stock Units, vesting in three equal annual installments beginning May 24, 2021.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.32 to $7.53, inclusive. The Reporting Person undertakes to provide to Quotient Limited and any security holder of Quotient Limited, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (13) to this Form 4.